{"id":78770,"date":"2026-09-04T16:16:32","date_gmt":"2026-09-04T08:16:32","guid":{"rendered":"https:\/\/flcube.com\/?p=78770"},"modified":"2026-09-04T16:16:33","modified_gmt":"2026-09-04T08:16:33","slug":"typewriter-therapeutics-raises-usd-56-million-series-a-to-advance-tprt-rna-gene-insertion-platform-for-in-vivo-car-t-and-liver-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78770","title":{"rendered":"Typewriter Therapeutics Raises USD 56 Million Series A to Advance TPRT RNA Gene Insertion Platform for In Vivo CAR-T and Liver Diseases"},"content":{"rendered":"\n

Typewriter Therapeutics<\/strong> announced the completion of a USD 56 million Series A financing<\/strong> to develop its RNA-based gene insertion technology platform<\/strong>, with R&D focused on in vivo CAR-T therapies<\/strong> and hereditary liver diseases<\/strong>. Built on the company\u2019s proprietary Targeted Primed Reverse Transcription (TPRT)<\/strong> platform, the all-RNA approach enables in vivo gene editing without viral vectors \u2014 and the company plans to initiate its first non-human primate studies by the end of 2026<\/strong>.<\/p>\n\n\n\n

Financing Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Company<\/td>Typewriter Therapeutics<\/strong><\/td><\/tr>
Round<\/td>Series A<\/td><\/tr>
Amount<\/td>USD 56 million<\/strong><\/td><\/tr>
Date<\/td>02 Sept 2026<\/td><\/tr>
Use of Proceeds<\/td>Development of RNA-based gene insertion platform; R&D in in vivo CAR-T<\/strong> and hereditary liver diseases<\/strong><\/td><\/tr>
Key Milestone<\/td>First non-human primate studies<\/strong> planned by end of 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Platform: Targeted Primed Reverse Transcription (TPRT)<\/h2>\n\n\n\n